HomeDiscoveryPipelineOnvansertib (NMS-937/ PCM-075)

Onvansertib (NMS-937/ PCM-075)

Onvansertib (NMS-937) is an orally available potent inhibitor of the PLK1 kinase, which is overexpressed and activated in proliferating cancer cells and with potential to be a “first-in-class” drug with respect to this molecular target. The drug was invented and developed into Phase I by NMS, then licensed to the US Biotech Trovagene, now Cardiff Oncology, which is continuing the development of the drug in AML in a phase Ib/II study in combination with cytarabine. The drug is also being investigated in a phase II study in combination with zytiga in patients with castration resistant prostate cancer and in a Phase Ib/II study in combination with FOLFIRI/bevacizumab for second line treatment of metastatic colorectal cancer in patients with a KRAS mutation.